Natera (NTRA) FY 2025 Conference June 09, 2025 02:00 PM ET Speaker0 Welcome, everybody. Good afternoon. Matt Sykes, the Life Science Tools and Diagnostics Analyst at Goldman Sachs, and I have the pleasure of welcoming Mike Brophy, CFO of Natera. Mike, thanks for being here. Yes. Thanks for having me. Maybe if we just start off with sort of a quick recap of first quarter results. Another really strong quarter of growth with record Signatera incremental units. What were the highlights from your perspective? I ...

Natera (NASDAQ: NTRA ) is a genetic testing company, with focuses on oncology, women's health, and organ health. Their signature product, Signatera, can help predict the efficacy of many forms of cancer treatment. Natera has alsoLike millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37478 (Registrant's Telephone Number, Including Area Code) NATERA, INC. (Exact Name of Registrant as Specifie ...

Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.25%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.42 per share when it actually produced a loss of $0.41, delivering a surprise of 2.38%.Over the last four quarters, the company has su ...

Natera (NTRA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Mike Brophy - Chief Financial OfficerSteve Chapman - Chief Executive OfficerSolomon Moshkevich - President of Clinical DiagnosticsAlexey Aleshin - GM of Oncology and ECD & Chief Medical OfficerNoah Kava - Equity Research AssociateColleen Babington - Equity Research AssociatePuneet Souda - Senior MD Conference Call Participants Daniel Brennan - AnalystTejas Savant - Executive Director & Senior Healthcare Equity AnalystRachel Va ...

Natera (NTRA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Welcome to Natera's twenty twenty five First Quarter Financial Results Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a reminder, this conference call is being recorded today, 05/08/2025. I would now like to turn the conference call over to Michael Brophy, Chief Financial Officer. Please go ahead. Speaker1 Thanks, operator. Good afterno ...

Natera, Inc. Q1'2025 Earnings Presentation May 8, 2025 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partnerships and potential acquisiti ...

Exhibit 99.1 Natera Reports First Quarter 2025 Financial Results AUSTIN, Texas, May 8, 2025 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights "We delivered another strong quarter, with volume growth across the business, including a record growth quarter for Signatera," said Steve Chapman, chief executive officer of Natera. "Our progress ...

文章核心观点 - Natera Inc.是一个强劲的增长案例，其基因检测业务组合支撑高利润率、公司再投资和持续两位数增长率 [1] 公司情况 - Natera Inc.在2024年第四季度财报中再次证实其增长态势 [1] - 公司基因检测业务组合支持高利润率、再投资和两位数增长 [1]

文章核心观点 - 公司2024年第四季度财报显示营收增长、亏损收窄且超预期，部分关键指标表现良好，但近一个月股价表现不佳 [1][3] 公司财务表现 - 2024年第四季度营收4.7606亿美元，同比增长53%，高于Zacks一致预期的4.7192亿美元，超预期幅度为0.88% [1] - 该季度每股收益为 - 0.41美元，去年同期为 - 0.64美元，超预期幅度为2.38%，一致预期为 - 0.42美元 [1] 公司股价表现 - 过去一个月公司股价回报率为 - 19.2%，而Zacks标准普尔500综合指数变化为 - 5.6% [3] - 公司股票目前Zacks排名为3（持有），表明短期内表现可能与大盘一致 [3] 公司关键指标表现 - 处理测试量为792,800，高于三位分析师平均估计的771,561 [4] - 许可及其他收入为315万美元，低于四位分析师平均估计的348万美元，同比变化为 - 18.3% [4] - 产品收入为4.729亿美元，高于四位分析师平均估计的4.0647亿美元，同比变化为 + 53.9% [4]